Maritsa Margaroni

Dr. Maritsa Margaroni

Pasteur Hellenic Institute, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Molecular and Cellular Probes
Verified
Journal Article
Closed access
Dimitra ToubanakiDimitra Toubanaki
Dimitra Toubanaki
MMMaritsa Margaroni
Maritsa Margaroni
EKEvdokia Karagouni
Evdokia Karagouni

30 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
Maria AgallouMaria Agallou
Maria Agallou
MMMaritsa Margaroni
Maritsa Margaroni
SKStathis D. Kotsakis
Stathis D. Kotsakis
EKEvdokia Karagouni
Evdokia Karagouni
Leishmaniases are complex vector-borne diseases caused by intracellular parasites of the genus Leishmania. The visceral form of the disease affects both humans and canids in tropical, subtropical, and Mediterranean regions. One health approach has suggested that controlling zoonotic visceral leishmaniasis (ZVL) could have an impact on the reduction of the human incidence of visceral leishmaniasis (VL). Despite the fact that a preventive vaccination could help with leishmaniasis elimination, effective vaccines that are able to elicit protective immune responses are currently lacking. In the present study, we designed a chimeric multi-epitope protein composed of multiple CD8+ and CD4+ T cell epitopes which were obtained from six highly immunogenic proteins previously identified by an immunoproteomics approach, and the N-termini of the heparin-binding hemagglutinin (HBHA) of Mycobacterium tuberculosis served as an adjuvant. A preclinical evaluation of the candidate vaccine in BALB/c mice showed that when it was given along with the adjuvant Addavax it was able to induce strong immune responses. Cellular responses were dominated by the presence of central and effector multifunctional CD4+ and CD8+ T memory cells. Importantly, the vaccination reduced the parasite burden in both short-term and long-term vaccinated mice challenged with Leishmania infantum. Protection was characterized by the continuing presence of IFN-γ+TNFα+-producing CD8+ and CD4+ T cells and increased NO levels. The depletion of CD8+ T cells in short-term vaccinated mice conferred a significant loss of protection in both target organs of the parasite, indicating a significant involvement of this population in the protection against L. infantum challenge. Thus, the overall data could be considered to be a proof-of-concept that the design of efficacious T cell vaccines with the help of reverse vaccinology approaches is possible.

30 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
MMMaritsa Margaroni
Maritsa Margaroni
Maria AgallouMaria Agallou
Maria Agallou
ETEvgenia Tsanaktsidou
Evgenia Tsanaktsidou
Olga KammonaOlga Kammona
Olga Kammona
CKCostas Kiparissides
Costas Kiparissides
EKEvdokia Karagouni
Evdokia Karagouni
Leishmaniasis is a vector-borne disease caused by an intracellular parasite of the genus Leishmania with different clinical manifestations that affect millions of people worldwide, while the visceral form may be fatal if left untreated. Since the available chemotherapeutic agents are not satisfactory, vaccination emerges as the most promising strategy for confronting leishmaniasis. In the present study, a reverse vaccinology approach was adopted to design a pipeline starting from proteome analysis of three different Leishmania species and ending with the selection of a pool of MHCI- and MHCII-binding epitopes. Epitopes from five parasite proteins were retrieved and fused to construct a multi-epitope chimeric protein, named LeishChim. Immunoinformatics analyses indicated that LeishChim was a stable, non-allergenic and immunogenic protein that could bind strongly onto MHCI and MHCII molecules, suggesting it as a potentially safe and effective vaccine candidate. Preclinical evaluation validated the in silico prediction, since the LeishChim protein, encapsulated simultaneously with monophosphoryl lipid A (MPLA) into poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles, elicited specific cellular immune responses when administered to BALB/c mice. These were characterized by the development of memory CD4+ T cells, as well as IFNγ- and TNFα-producing CD4+ and CD8+ T cells, supporting the potential of LeishChim as a vaccine candidate.

22 June 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MMMaritsa Margaroni
Maritsa Margaroni
Maria AgallouMaria Agallou
Maria Agallou
AVAthina Vasilakaki
Athina Vasilakaki
DKDimitra Karagkouni
Dimitra Karagkouni
GSGiorgos Skoufos
Giorgos Skoufos
EKEvdokia Karagouni
Evdokia Karagouni
Leishmania parasites are capable of effectively invading dendritic cells (DCs), a cell population orchestrating immune responses against several diseases, including leishmaniasis, by bridging innate and adaptive immunity. Leishmania on the other hand has evolved various mechanisms to subvert DCs activation and establish infection. Thus, the transcriptional profile of DCs derived from bone marrow (BMDCs) that have been infected with Leishmania infantum parasite or of DCs exposed to chemically inactivated parasites was investigated via RNA sequencing, aiming to better understand the host–pathogen interplay. Flow cytometry analysis revealed that L. infantum actively inhibits maturation of not only infected but also bystander BMDCs. Analysis of double-sorted L. infantum infected BMDCs revealed significantly increased expression of genes mainly associated with metabolism and particularly glycolysis. Moreover, differentially expressed genes (DEGs) related to DC-T cell interactions were also found to be upregulated exclusively in infected BMDCs. On the contrary, transcriptome analysis of fixed parasites containing BMDCs indicated that energy production was mediated through TCA cycle and oxidative phosphorylation. In addition, DEGs related to differentiation of DCs leading to activation and differentiation of Th17 subpopulations were detected. These findings suggest an important role of metabolism on DCs-Leishmania interplay and eventually disease establishment.

22 November 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMaritsa Margaroni
Maritsa Margaroni
ETEvgenia Tsanaktsidou
Evgenia Tsanaktsidou
Maria AgallouMaria Agallou
Maria Agallou
CKCostas Kiparissides
Costas Kiparissides
Olga KammonaOlga Kammona
Olga Kammona
EKEvdokia Karagouni
Evdokia Karagouni

19 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Maria AgallouMaria Agallou
Maria Agallou
MMMaritsa Margaroni
Maritsa Margaroni
EKEvdokia Karagouni
Evdokia Karagouni
Control of the intracellular parasite Leishmania (L.) requires the activation of strong type 1 cellular immune responses. Towards this goal, in the present study, a multiepitope chimeric protein named LiChimera was encapsulated into cationic liposomes and its protective efficacy against experimental visceral leishmaniasis was investigated. Liposomal LiChimera conferred significant protection against L. infantum as evidenced by the significantly reduced parasite loads in the spleen and liver. Protection detected in Lipo:LiChimera-immunized mice was dependent on the differentiation of long-lasting cellular immune responses and particularly the induction of antigen-specific multifunctional memory CD4+ TH1 and CD8+ T cells that persisted during infection, as evidenced by the persistent high production of IFN-γ and IL-2 and proliferation activity. Notably, protected mice were also characterized by significantly low numbers of non-regulatory CD4+ T cells able to co-produce IFN-γ and IL-10, an important population for disease establishment, as compared to non-immunized control group. Collectively, these results demonstrate that cationic liposomes containing LiChimera can be considered an effective candidate vaccine against visceral leishmaniasis.